# Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

> **NCT02277743** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 671 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo (for Dupilumab)

## Key facts

- **NCT ID:** NCT02277743
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-11
- **Final completion:** 2016-02
- **Target enrollment:** 671 (ACTUAL)
- **Last updated:** 2017-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02277743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02277743, "Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02277743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*